Nurix Therapeutics Stock Current Asset
| NRIX Stock | USD 20.89 0.60 2.79% |
Nurix Therapeutics fundamentals help investors to digest information that contributes to Nurix Therapeutics' financial success or failures. It also enables traders to predict the movement of Nurix Stock. The fundamental analysis module provides a way to measure Nurix Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nurix Therapeutics stock.
Non Current Assets Total is likely to rise to about 79.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 6.5 M in 2024. Nurix | Current Asset |
Nurix Therapeutics Company Current Asset Analysis
Nurix Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Nurix Current Asset Historical Pattern
Today, most investors in Nurix Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nurix Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Nurix Therapeutics current asset as a starting point in their analysis.
Nurix Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Nurix Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Nurix Therapeutics has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Nurix Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nurix Therapeutics from analyzing Nurix Therapeutics' financial statements. These drivers represent accounts that assess Nurix Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nurix Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 668.0M | 1.2B | 602.3M | 338.0M | 304.2M | 518.5M | |
| Enterprise Value | 548.6M | 1.2B | 549.7M | 314.0M | 282.6M | 475.4M |
Nurix Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nurix Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nurix Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Nurix Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (4.34) % | ||||
| Current Valuation | 1.1 B | ||||
| Shares Outstanding | 70.84 M | ||||
| Shares Owned By Insiders | 1.45 % | ||||
| Shares Owned By Institutions | 98.33 % | ||||
| Number Of Shares Shorted | 9.6 M | ||||
| Price To Book | 4.04 X | ||||
| Price To Sales | 26.98 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | (145.87 M) | ||||
| EBITDA | (141.41 M) | ||||
| Net Income | (143.95 M) | ||||
| Cash And Equivalents | 344.48 M | ||||
| Cash Per Share | 7.31 X | ||||
| Total Debt | 30.61 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.26 X | ||||
| Book Value Per Share | 5.62 X | ||||
| Cash Flow From Operations | (81.36 M) | ||||
| Short Ratio | 9.83 X | ||||
| Earnings Per Share | (2.90) X | ||||
| Target Price | 31.2 | ||||
| Number Of Employees | 284 | ||||
| Beta | 2.2 | ||||
| Market Capitalization | 1.52 B | ||||
| Total Asset | 355.6 M | ||||
| Retained Earnings | (545.2 M) | ||||
| Working Capital | 208.54 M | ||||
| Net Asset | 355.6 M |
About Nurix Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nurix Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.